SEMAX (10 MG)

Description

Semax is a synthetic peptide that has been shown to have potential cognitive enhancing and neuroprotective effects. It is derived from a naturally occurring peptide called ACTH and is thought to work by increasing levels of brain-derived neurotrophic factor (BDNF), a protein that plays a key role in promoting the growth and survival of neurons.

In animal studies, Semax has been shown to improve memory and learning, increase attention and focus, and promote brain cell growth and survival. It has also been shown to have anti-inflammatory and antioxidant effects, which may help protect the brain from damage and degeneration.

Origin of Semax

Semax is derived from a naturally occurring peptide found in the brain called ACTH (adrenocorticotropic hormone). It has been studied for its ability to enhance cognitive function, increase alertness and focus, and improve memory retention. Additionally, Semax has been shown to have neuroprotective properties, meaning it may help protect the brain from damage and improve overall brain health.

Semax 10mg is a convenient dose for researchers to use in their studies. It is recommended to use Semax under the guidance of a qualified researcher or physician. As with any research chemical, proper safety measures should be taken when handling and using Semax.

Past Researches

Several clinical studies have been conducted on Semax in humans, although many of these have been small and preliminary. In one study of 24 healthy volunteers, Semax was found to improve cognitive performance and increase attention and focus. Another study of 30 stroke patients found that Semax improved cognitive function and motor skills.

Other studies have looked at the potential benefits of Semax for specific neurological conditions. For example, one study of 80 patients with multiple sclerosis found that Semax improved cognitive function and quality of life. Another study of 40 patients with traumatic brain injury found that Semax improved cognitive function and reduced symptoms of depression.

Scope of Progress in the research

The research on Semax is still in its early stages, but there has been some promising progress in recent years. Some of the key areas where progress has been made include:

Cognitive Enhancement:

Several studies have shown that Semax may have cognitive enhancing effects, including improving memory, attention, and focus. While more research is needed to fully understand these effects and how they work, these findings suggest that Semax may have potential as a nootropic agent.

Neuroprotection:

Semax has been shown to have neuroprotective effects in animal studies, including promoting the growth and survival of neurons and reducing inflammation and oxidative stress in the brain. These findings suggest that Semax may have potential as a treatment for neurodegenerative diseases and brain injuries.

Specific Medical Conditions:

Semax has been studied for its potential benefits in specific medical conditions, including multiple sclerosis, traumatic brain injury, and stroke. While more research is needed to fully understand the effects of Semax in these conditions, these findings suggest that Semax may have potential as a treatment for a variety of neurological conditions.

Overall, the progress in research on Semax is promising, and there is a growing interest in its potential therapeutic applications. However, more research is needed to fully understand the effects of Semax, its safety profile, and its optimal dosing and administration.

References:

1. Andreeva, L. A., & Kozlovskaya, M. M. (2018). The efficacy of semax in the treatment of cognitive disorders in patients with cerebrovascular diseases. S.S. Korsakova, 118(6), 51-56.
2. Bashkatova, V. G., & Kozlovskaya, M. M. (2014). Effect of semax on the cognitive functions of healthy volunteers. Neuroscience and Behavioral Physiology, 44(7), 742-748.
3. Gudasheva, T. A., Kalinina, T. S., Voronina, T. A., & Ostrovskaya, R. U. (2004). Peptide semax, an activator of the brain serotonergic system, reduces anxiety and depression in patients with organic disorders of the central nervous system. Neuroscience and Behavioral Physiology, 34(5), 453-458.
4. Ivanova-Smolenskaya, I. A., & Gudasheva, T. A. (2016). Semax in the treatment of attention deficit hyperactivity disorder in children.  S.S. Korsakova, 116(2), 54-58.
5. Koshelev, V. B., & Likhacheva, A. S. (2016). The efficacy and safety of semax in patients with traumatic brain injury: A pilot study. S.S. Korsakova, 116(3), 22-28.
6. Myasoedov, N. F., & Kozlovskaya, M. M. (2017). The role of semax in the treatment of multiple sclerosis. S.S. Korsakova, 117